Contents
Volume 70 Supplement 1 | THORAX June 2015

i1 Summary of recommendations and good practice points

i5 Introduction
i5 Target audience for the guideline
i5 Groups covered
i5 Scope of the guideline
i5 Areas not covered by the guideline
i6 Methodology
i6 Clinical questions and literature search
i6 Appraisal of the literature
i6 Considered judgement and grading of evidence
i7 Drafting the guideline
i7 Declarations of Interest
i7 Acknowledgements
i8 Audit and research recommendations
i8 Glossary/Abbreviations and symbols

i8 Long Term Oxygen Therapy
i8 Evidence for use of LTOT in patients with COPD
i8 Survival benefit in COPD patients with LTOT
i8 Evidence for blood gas criteria for selection of COPD patients for LTOT
i9 LTOT in hypercapnic COPD patients
i9 Effects of LTOT on pulmonary haemodynamics in COPD patients
i9 Effects of LTOT on sleep in COPD patients
i9 Effects of LTOT on quality of life and neuropsychological function in COPD patients
i9 LTOT in COPD patients and impact on hospital admission
i9 Other effects of LTOT in COPD patients
i9 Evidence for use of LTOT in patients with other respiratory or cardiac disease
i9 LTOT in patients with ILD
i9 LTOT in patients with CF
i9 LTOT in patients with pulmonary hypertension
i9 LTOT in patient with neuromuscular or chest wall disorders
i9 LTOT in patients with advanced cardiac failure
i9 Outcomes of LTOT in patients who continue to smoke

i11 Referral and assessment of patients for LTOT
i11 Patient information on referral for home oxygen assessment
i11 Use of oximetry as a screening tool for patient selection for LTOT
i11 Referral for home oxygen at hospital discharge
i12 Use of pulse oximetry, ABGs and CBGs in assessment for LTOT
i13 Management of hypercapnia during LTOT assessment
i13 Use of LTOT: hours of use and flow rates
i14 LTOT flow rates

i15 Nocturnal Oxygen Therapy
i15 NOT in COPD patients with nocturnal desaturation
i16 NOT in patients with cardiac disease and nocturnal desaturation
i16 Effect of NOT on SDB in severe cardiac disease
i16 Effect of NOT on cardiac function in severe cardiac disease
i17 Effect of NOT on quality of life, activity and cognition in severe cardiac disease
i17 Effect of NOT on healthcare utilisation or mortality
i17 NOT in patients with other respiratory diseases and nocturnal desaturation
i18 Use of NOT in patients with CF
i18 Use of NOT in patients with ILD
i18 Use of NOT in patients with neuromuscular weakness
i18 Use of NOT in patients with Cheyne-Stokes respiration, obesity hypventilation syndrome and overlap syndrome

i18 Ambulatory Oxygen Therapy
i18 AOT in patients not eligible for LTOT
i18 Use of AOT during exercise
i19 Long term impact of AOT
i19 AOT in patients eligible for LTOT
i19 Assessment for AOT

i20 Palliative Oxygen Therapy
i20 Effects of POT in comparison with air
i20 Effects of POT in comparison with other therapies such as opiates, fan therapy and cognitive behavioural therapy

i20 Palliative Oxygen Therapy
i20 Effects of POT in comparison with air
i20 Effects of POT in comparison with other therapies such as opiates, fan therapy and cognitive behavioural therapy

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme. See http://thorax.bmj.com/site/about/guidelines.xhtml#open

C O P E | COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

www.publicationethics.org.uk
i21 Short Burst Oxygen Therapy
i21 Use of SBOT in respiratory disease
i22 Use of SBOT in CH

i22 Equipment for home oxygen therapy
i22 Oxygen source: concentrators, cylinders, liquid oxygen – description and indications for use
i22 Concentrators
i23 Home concentrators
i23 Transportable and portable concentrators
i23 Cylinder oxygen
i23 Liquid oxygen
i23 Comparison of different oxygen sources in clinical trials
i23 Use of portable oxygen to delivery ambulatory oxygen
i24 Use of portable oxygen to deliver LTOT
i24 Static cylinder use
i24 Oxygen delivery: nasal cannulae and masks, oxygen-conserving devices and trans-tracheal devices – description and indications for use
i24 Nasal cannulae and masks
i24 Oxygen-conserving devices
i25 Trans-tracheal oxygen
i25 Other equipment: trolleys and backpacks, humidifiers – descriptions and indications for use
i25 Humidification
i25 Carrying home oxygen: trolleys and backpacks

i25 Safety and Home Oxygen Therapy
i25 Smoking and home oxygen therapy
i26 Role of risk assessments
i26 Responsibilities of the oxygen supplier
i26 Role of fire and rescue services
i26 Trips and falls

i27 Conclusion

i27 References

i31 Appendices
i31 Appendix 1: Protocol for ambulatory oxygen therapy assessment
i34 Appendix 2: Assessment referral form
i35 Appendix 3: Assessment protocol for palliative oxygen
i36 Appendix 4: Risk assessment tools
i41 Appendix 5: Home oxygen order forms (HOOF) and home oxygen consent forms (HOCF) forms
i41 Appendix 6: Sample patient information leaflets
i42 Appendix 7: Practical points for removal of home oxygen
i43 Appendix 8: Guideline group members

Online appendices
Web Appendix 9: PICO questions
Web Appendix 10: Literature search details
Web Appendix 11: Evidence tables
Web Appendix 12: Home oxygen equipment